Galderma

Key Findings

• Economic: Galderma Holding SA’s US dermatology licences with Israeli-incorporated Sol-Gel generated USD 1.482 million in recognised royalty revenue for Sol-Gel in 2024 and USD 711,000 in 2025. The licences terminated effective 17 April 2025; the revenue figures do not independently establish cash-transfer dates or continued licensing after termination.^{1, 2}
• Economic: Israeli regulatory documents identify AMI Technologies as registration holder for Galderma-manufactured Soolantra, Epiduo and Aklief. The Aklief document was revised in May 2025; these records do not establish a Galderma-owned Israeli subsidiary, shipment volumes or settlement destinations.^{3, 4, 5}
• Political: A Brands2Boycott campaign page lists Cetaphil and Sculptra. No public evidence identified in the political audit establishing Galderma as an official BDS Movement priority boycott target.^{6, 7}
• Not found: No public evidence identified of Galderma-specific Israeli military procurement, weapons supply, surveillance deployment or government-cloud provision. The documented pharmaceutical licences and aesthetic consultation technology concern civilian applications.^{2, 8, 9, 10}

Target Profile

Executive Summary

Galderma’s documented Israel-related activity is principally civilian pharmaceutical commerce. Israeli regulatory records identify French-manufactured Soolantra, Epiduo and Aklief with AMI Technologies or A.M.I. Medical Technologies Limited as their Israeli registration holder. Separately, Rafa Laboratories described a longstanding partnership commercialising Galderma brands in Israel, corroborated by a pharmaceutical directory. These sources establish market relationships but do not quantify Galderma’s Israeli sales or identify particular settlement customers, military purchasers or shipment destinations.^{3, 4, 5, 18, 19, 20}

The clearest quantified economic relationship was with Sol-Gel Technologies Ltd., an Israeli-incorporated biotechnology company based in Ness Ziona. Galderma Holding SA licensed US commercialisation rights for Twyneo and Epsolay under agreements dated 25 June 2021. Sol-Gel’s financial-statement notes record USD 1.482 million in associated royalty revenue for 2024 and USD 711,000 for 2025. Those figures establish recognised revenue attributable to the agreements, rather than independently verified cash transfers, net profits or expenditure on particular Israeli employees or facilities.^{1, 2}

The Sol-Gel relationship continued beyond the audits’ July and November 2024 chronology markers but terminated effective 17 April 2025. A subsequent Mayne Pharma arrangement was a separate transaction and must not be attributed to Galderma. Termination materially limits the historical licensing finding, although it does not establish a complete exit from Israel: the separate Aklief registration documentation was revised in May 2025, and no public evidence identified its formal termination by the research cutoff.^{1, 2, 5}

The military and digital audits identified no public evidence of Israeli defence procurement, weapons components, military logistics, surveillance systems, military AI or government-cloud services attributable to Galderma. Its FACE application uses facial assessment and augmented reality for aesthetic consultations; that functionality does not establish biometric identification or surveillance. The political audit likewise identified no verified military-support donations, settlement sponsorship or Israel-Palestine lobbying campaign. Consumer campaign listings and L’Oréal’s minority ownership require careful attribution and do not independently establish those activities.^{2, 6, 8, 9, 10, 12, 14}

The fixed, human-vetted V6.6 outcome is BRS 360, Tier D (Moderate Complicity). The assessment is concentrated in Economic, whose domain score is 4.32; Military, Digital and Political each score 0.00. This classification preserves the documented economic nexus while retaining the termination, civilian-purpose and entity-attribution limits.

Timeline of Relevant Events

Corporate Overview

Galderma is a Swiss dermatology group headquartered in Zug. Its business comprises Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology; it reported USD 5.207 billion in 2025 net sales. Its corporate history records the Nestlé–L’Oréal joint venture, subsequent Nestlé ownership, institutional acquisition and Swiss public listing.^{11, 13, 21, 22}

The economic audit distinguishes three Israeli commercial relationships. AMI appears in medicine-specific regulatory documents as registration holder. Rafa appears in a company-authored partnership statement and an independent pharmaceutical directory as a commercial partner. Sol-Gel was the Israeli contractual counterparty to Galderma Holding SA’s historical US licences. None of those relationships establishes that the counterparty was a Galderma-controlled subsidiary.^{1, 2, 3, 4, 5, 18, 19}

The examined 2025 consolidated company list did not identify an Israeli-incorporated controlled operating subsidiary. Galderma’s manufacturing disclosure identifies facilities in Canada, Sweden, France and Brazil. Its Middle East webpage identifies Galderma International SAS and a Dubai regional contact address. No public evidence identified of a directly operated Galderma Israeli factory, office, warehouse or research centre.^{11, 25, 26}

L’Oréal’s 20% holding and two board representatives establish significant influence. They do not establish that Galderma controls L’Oréal’s Israeli operations, that L’Oréal became party to the Sol-Gel licences, or that shareholder-group activities can automatically be attributed to Galderma. The executed licensing termination agreement names Galderma Holding SA and Sol-Gel Technologies Ltd. as its parties.^{2, 14, 17}

Domain Summaries

Military: Military

Mechanism of Involvement

No public evidence identified of a Galderma-specific contract with the Israeli Ministry of Defence, IDF, Israel Prison Service, Border Police or another Israeli military or security institution. The military audit found no documented weapons supply, defence-prime integration, military logistics, military construction or purpose-built weapons software.

The relevant documentary distinction is between civilian medicines and established military procurement. Israel’s Ministry of Defence solicits potential suppliers of medicines and medical equipment, but its general procurement page does not identify Galderma as an awarded supplier. Galderma’s reporting describes dermatology operations, and its Restylane materials describe aesthetic applications.^{10, 13, 27}

The Sol-Gel agreements establish civilian pharmaceutical commercialisation rights in the United States. They do not identify Israeli military end-users, defence procurement or military-specific product variants.^{1, 2}

Counter-Arguments and Evidence Limits

Galderma’s strongest defence is the absence of a verified military transaction combined with the documented civilian character of its portfolio. A medicine’s possible use by military personnel does not establish a corporate military supply relationship. Nor does a procurement authority’s general invitation to medical suppliers establish a Galderma contract.^{10, 13, 27}

No public evidence identified of Galderma supplying Israeli defence primes, supporting bases, transporting military cargo or providing settlement-construction equipment. The military audit also did not establish Galderma’s inclusion in the examined OHCHR settlement-business reporting. The reporting’s existence is contextual evidence, not a Galderma-specific finding.²⁸

These are bounded search findings, not guarantees that undisclosed transactions cannot exist. On the reviewed record, the fixed Military score is 0.00.

Named Entities and Evidence Map

Digital: Digital

Mechanism of Involvement

Galderma has documented digital products, but the digital audit did not establish an Israeli digital-infrastructure nexus. FACE by Galderma, announced in January 2023 and launched in the United States in March 2023, was developed with Crisalix. It supports facial assessment, augmented-reality treatment simulation and patient-management functions, including treatment records, appointments, images and individual profiles.^{8, 9}

Those functions establish clinical image processing and patient-data handling. They do not establish facial identity matching, policing, population monitoring or military surveillance. No public evidence identified that Crisalix supplied Israeli-origin technology or that FACE used infrastructure within Israeli jurisdiction. Its public launch materials do not disclose physical hosting locations or establish transfers to Israeli state institutions.^{8, 9}

Galderma also publicly described an AI Framework, AI Center of Excellence and predictive and generative AI projects. No public evidence identified connecting those programmes to an Israeli-origin enterprise vendor, Israeli military AI supplier or Israeli-operated model infrastructure.²⁹

Counter-Arguments and Evidence Limits

The strongest defence is the distinction between aesthetic assessment and surveillance. Facial analysis alone does not establish biometric identification, security-sector deployment or an Israeli technology relationship. Likewise, undisclosed hosting arrangements are an information gap, not evidence of Israeli data residency.^{8, 9}

The Sol-Gel relationship involved pharmaceutical microencapsulation technology and prescription dermatology products. Its Israeli counterparty does not convert that relationship into a cybersecurity, enterprise-cloud or surveillance finding.^{1, 2}

No public evidence identified of Galderma participation in Project Nimbus, Israeli government-cloud provision, offensive cyber, military targeting AI or settlement-specific digital services. The fixed Digital score is 0.00.

Named Entities and Evidence Map

Economic: Economic

Mechanism of Involvement

The economic record contains both Israeli market access and a quantified historical licensing relationship.

First, Israeli regulatory documents identify AMI Technologies as registration holder for Soolantra and Epiduo in June 2023. Aklief information revised in May 2025 identifies A.M.I. Medical Technologies Limited at Hanagar 22, Hod Hasharon. All three documents identify Laboratoires Galderma in France as manufacturer. They establish product-specific regulatory relationships, without establishing AMI’s ownership, contractual importer-of-record status or transaction volumes.^{3, 4, 5}

Second, Rafa’s approximately 2022 statement describes a longstanding Galderma partnership and visiting representatives Robert Bitner, Veronika Dubitskaya, Monika Lamparska-Kania and Karolina Zabuska. An independent pharmaceutical directory corroborates the partner relationship. Rafa’s broader business covers public and private healthcare institutions, clinics and pharmacies, but the disclosures do not allocate specific Galderma products to particular institutional customers.^{18, 19, 20}

Third, Galderma Holding SA’s agreements with Sol-Gel created a direct contractual relationship with an Israeli biotechnology company. The licences covered US commercialisation of Twyneo and Epsolay. Sol-Gel recognised USD 1.482 million in agreement-specific royalties in 2024 and USD 711,000 in 2025, totalling USD 2.193 million across those years.^{1, 2}

The economic audit retained those precise amounts because the financial-statement notes and geographical revenue disclosures corroborate them. Sol-Gel’s narrative discussion separately gives USD 1.6 million for 2024, an unexplained USD 118,000 difference from USD 1.482 million. The discrepancy remains unresolved; it is not treated as conventional rounding or additional verified Galderma expenditure.^{1, 30}

Sol-Gel reported 28 employees, all in Israel, at 31 December 2025. Those employees belonged to Sol-Gel’s entire business. No public evidence identified allocating a particular number of jobs, payroll costs, research projects or tax payments to Galderma-related royalties.¹

Counter-Arguments and Evidence Limits

The strongest mitigation is the executed termination: the original licences ended effective 17 April 2025. They therefore continued beyond July and November 2024 but were no longer operative at the October 2026 cutoff. No public evidence identified of a replacement Galderma–Sol-Gel commercialisation agreement.^{1, 2}

Sol-Gel’s separate Mayne transaction must be excluded from Galderma attribution. Likewise, 2025 royalty recognition does not establish continued licensing after termination or the timing of cash settlement. The USD 433,000 recognised in the first half of 2025 falls within a reporting period extending beyond termination; it does not override the agreement’s effective end date.^{1, 2, 31}

The agreements concerned the United States, not documented Israeli retail sales or settlement destinations. No public evidence identified linking the royalties to military procurement, settlement production or occupied-territory customers. Nor do the agreements establish Galderma ownership of Sol-Gel or operation of its Israeli facilities.^{1, 2}

Termination does not erase every separate Israel-related relationship. The May 2025 Aklief record postdates the Sol-Gel termination, but remains a regulatory record rather than proof of a particular sale. No public evidence identified quantifying subsequent Israeli revenue, shipments, employment or tax payments attributable to Galderma.⁵

The fixed Economic inputs are I=5.50, M=7.00 and P=5.50, producing 4.32. The evidentiary basis is documented pharmaceutical market participation and direct historical licensing, with termination and attribution limits retained.

Named Entities and Evidence Map

Political: Political

Mechanism of Involvement

The political record is limited. Brands2Boycott lists Galderma-associated Cetaphil and Sculptra in consumer boycott guidance, connecting them with historical investor relationships. This documents campaign scrutiny, rather than independently verifying the underlying allegations. No public evidence identified in the reviewed BDS Movement material establishing Galderma as an official priority target.^{6, 7}

L’Oréal’s increased shareholding and two board representatives establish a governance relationship. They do not establish an Israeli state mandate, Galderma-directed political advocacy or responsibility for every activity elsewhere in the shareholder group.^{14, 17}

No public evidence identified of an attributable official Galderma statement endorsing Israeli military operations, a verified Israel-Palestine lobbying campaign, military-support donations, settlement sponsorship or an Israel-specific reservist subsidy. Galderma’s public sustainability and governance materials articulate general stakeholder and ethical-business commitments; they do not establish a conflict-specific position.^{32, 33}

Counter-Arguments and Evidence Limits

Galderma’s strongest defence is the absence of verified political conduct of the kinds examined. Public silence does not establish endorsement. A consumer campaign listing does not establish official BDS designation, and minority shareholder connections do not establish Galderma control over another company’s Israeli operations.^{6, 7, 14}

The political audit could not independently verify a current distributor contract from its successfully retrieved primary documents. Other domain audits supplied specific AMI registrations and Rafa partnership evidence. Those findings can be combined without upgrading regulatory status or a historical partnership statement into a verified current distribution contract.^{3, 4, 5, 18, 19}

No public evidence identified of settlement premises, settlement-authority contracts, employee discipline over Israel-Palestine expression or leadership donations to the named military-support organisations examined.

The fixed Political inputs are I=2.00, M=0.00 and P=0.00, producing 0.00. The retained impact input must not be presented as proof of an unverified political act.

Named Entities and Evidence Map

Complicity Index Score

Method: V6.6. Final human-vetted values.

• V_MAX: 4.32 Avg_OTHERS: 0.00
• BRS Score: 360 Tier: D (Moderate Complicity)

Economic drives V_MAX through the documented Israeli pharmaceutical relationships and quantified historical Sol-Gel royalties, with the April 2025 termination expressly retained.^{1, 2, 3, 4, 5} The resulting BRS 360/Tier D classification uses the fixed, scale-free, evidence-only, vetted V6.6 method; it does not imply a verified military, digital or political-support mechanism. No separate reviewed narrative mapping each input to a numerical threshold was supplied, so this dossier preserves the values without inventing that derivation.

Methodology Note

• Evidence scope: This dossier synthesises only the four supplied domain audits. Research cutoffs are 25 October 2026 for Military, Digital and Economic, and 24 October 2026 for Political; it adds no independent investigation.
• Scale-free assessment: Impact measures activity type; Magnitude measures scale; Proximity measures directness. The final human-vetted inputs and outputs are reproduced unchanged.
• Temporal rule: Divested, exited or terminated activity is mitigated. The Sol-Gel termination controls the licensing end date; subsequent accounting recognition does not independently establish continued operation.^{1, 2}
• Entity attribution: No transitive guilt is applied. Registration holders, distributors, contractual counterparties, subsidiaries and minority shareholders retain their separate documented roles.
• Settlement rule: Verified settlement operations would count in both Economic and Political. No public evidence identified establishing such Galderma operations in the reviewed record.
• Negative and unresolved findings: “No public evidence identified” denotes the audits’ bounded search result. Unresolved discrepancies, undisclosed transaction details and unverified allegations remain qualified or are excluded.